Search results

Order by most recent / most popular / relevance

Results: 1-5 of 5

Supreme Court tightens the scope of antitrust immunity in Government-owned hospital mergers

Hogan Lovells
-
USA
-
February 22 2013

In a unanimous and favorable decision for the Federal Trade Commission (FTC), the Supreme Court found that the state action immunity doctrine does

Court to tackle "state action" for the first time in 20 years

Hogan Lovells
-
USA
-
October 23 2012

On 26 November, the U.S. Supreme Court will hear argument in FTC v. Phoebe Putney Health System, No. 11-1160, its first case in 20 years about "state action" immunity under the antitrust laws

FTC requires divestiture of pharmaceutical and medical data analytics components to clear IMS health’s acquisition of SDI health

Hogan Lovells
-
USA
-
June 12 2012

In October 2011, the FTC required Healthcare Technology Holdings, Inc. to divest SDI Health’s promotional audit and medical audit business lines in order for Health Technology’s subsidiary, IMS Health to consummate its acquisition of SDI

Antitrust, competition and economic regulation client quarterly newsletter

Hogan Lovells
-
China, European Union, Greece, USA
-
January 24 2012

A public company CEO recently consented to a federal district court order requiring him to pay a $500,000 civil penalty for violating the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR Act”

FDA's financial disclosure regulations: careful compliance in a changing landscape Part 1

Hogan Lovells
-
USA
-
January 14 2011

At first glance, compliance with US Food and Drug Administration (FDA) financial disclosure regulations set forth in 21 CFR Part 54 looks straightforward

Search results

Supreme Court tightens the scope of antitrust immunity in Government-owned hospital mergers

Court to tackle "state action" for the first time in 20 years

FTC requires divestiture of pharmaceutical and medical data analytics components to clear IMS health’s acquisition of SDI health

Antitrust, competition and economic regulation client quarterly newsletter

FDA's financial disclosure regulations: careful compliance in a changing landscape Part 1

Current Search

Suggested Facets

Author

Jurisdiction

Workarea